Business Context and Reporting Period
Company: InspireMD, Inc. (NSPR)
Filing Type: Form 10-Q (Unaudited)
Period Ended: March 31, 2025
Business Overview: InspireMD is a medical device company developing the CGuard™ stent platform for carotid artery disease. The company markets products internationally (primarily Europe) and is seeking FDA approval for its CGuard Prime system in the U.S., with approval expected in Q3 2025. Operations and manufacturing are primarily located in Israel.
Key Financial Metrics
| Metric | Q1 2025 | Q1 2024 |
|---|---|---|
| Revenue | $1,529,000 | $1,511,000 |
| Gross Profit | $292,000 | $292,000 |
| Gross Margin | 19.1% | 19.3% |
| Operating Loss | $(11,460,000) | $(7,414,000) |
| Net Loss | $(11,166,000) | $(7,032,000) |
| Net Loss Per Share (Basic/Diluted) | $(0.22) | $(0.21) |
| Cash and Cash Equivalents | $12,383,000 | $9,389,000 (Q1 2024 End) |
| Marketable Securities | $13,703,000 | $24,561,000 (Q1 2024 End) |
| Total Current Assets | $32,144,000 | $40,521,000 (Dec 31, 2024) |
| Total Current Liabilities | $7,367,000 | $7,678,000 (Dec 31, 2024) |
| Operating Cash Flow | $(8,792,000) | $(5,064,000) |
Material Changes vs. Prior Period
- Revenue: Increased 1.2% to $1.53 million, driven by growth in Latin America, Asia, and North America (clinical trial sales), offset by a decline in Europe due to distributor inventory management ahead of potential new product approvals.
- Operating Expenses: Total operating expenses surged 52.5% to $11.75 million.
- R&D: Increased 54.6% to $4.06 million due to SwitchGuard NPS development, regulatory costs for the CGUARDIANS II study, and U.S. expansion hiring.
- Selling & Marketing: Increased 122.3% to $2.75 million, primarily due to building U.S. commercial infrastructure and travel expenses.
- G&A: Increased 28.6% to $4.94 million, driven by compensation costs, headhunting fees, and rent for the new Miami headquarters.
- Liquidity: Cash and cash equivalents decreased by $6.53 million during the quarter. Total liquid assets (cash + marketable securities) stand at approximately $26.1 million.
Outlook, Risks, and Management Commentary
- Going Concern Warning: Management has expressed substantial doubt about the company's ability to continue as a going concern. The company does not have sufficient resources to fund operations for the next 12 months without additional financing.
- Capital Strategy: Plans to raise capital through equity sales, debt, strategic partnerships, or warrant exercises. The company has an active ATM program and outstanding warrants that could provide up to $71.4 million if fully exercised.
- Regulatory Milestones: FDA approval for the CGuard Prime carotid stent system is expected in Q3 2025. The company has also received FDA approval to initiate the CGUARDIANS II pivotal study for the CGuard Prime 80cm system.
- Geopolitical Risks: Operations and manufacturing are located in Israel. While currently unaffected, ongoing conflict poses risks to personnel availability, supply chains, and manufacturing continuity. The company is transitioning U.S. manufacturing to a contract manufacturer in North Carolina to mitigate this risk.
- Trade Policy: Potential U.S. tariffs on Israeli medical devices could materially increase cost of goods sold if manufacturing remains in Israel during the transition period.
Investor Verification Checklist
- Liquidity Runway: Verify the timeline and certainty of upcoming capital raises given the "substantial doubt" disclosure.
- FDA Approval Timeline: Monitor progress toward the expected Q3 2025 FDA approval for CGuard Prime, which is critical for U.S. revenue growth.
- Manufacturing Transition: Confirm the status of the manufacturing transfer from Israel to the Aptyx facility in North Carolina to assess exposure to Israeli geopolitical risks and potential tariffs.
- Expense Trajectory: Assess if the sharp increase in operating expenses (up 52% YoY) is sustainable relative to current revenue levels.
- Warrant Expiration: Review the terms of outstanding warrants (Series I, J, K) which are tied to specific regulatory and commercial milestones.